Insulin resistance means your cells do not respond well to insulin, so the pancreas may need to make more insulin to keep blood sugar normal. Diabetes means blood sugar is persistently too high because the body cannot make or use insulin well enough. Blood tests—not symptoms alone—tell the difference.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What is the simple difference between insulin resistance and diabetes?
Insulin resistance is a problem with insulin response; diabetes is a diagnosed blood sugar disorder. The key difference is whether blood glucose has crossed diagnostic thresholds on lab testing, often confirmed by repeat testing when there is no urgent situation 1, 2.
Insulin is a hormone made by the pancreas. It helps move glucose, or sugar, from the blood into muscle, fat, and liver cells so the body can use or store energy 1.
With insulin resistance, cells do not answer insulin’s signal as well. The pancreas may respond by making more insulin, called hyperinsulinemia. For a time, that extra insulin can keep blood glucose normal; later, glucose may rise into prediabetes or type 2 diabetes 1.
| Term | What it means | How clinicians check it | What it can lead to |
|---|---|---|---|
| Insulin resistance | Cells do not respond well to insulin; the pancreas may make more insulin | Risk review, metabolic labs, sometimes fasting insulin or specialist testing | Prediabetes, type 2 diabetes, metabolic syndrome |
| Prediabetes | Blood sugar is above normal but below diabetes range | A1C, fasting blood glucose, or oral glucose tolerance test | Higher risk of type 2 diabetes and heart disease |
| Type 2 diabetes | Blood sugar is persistently high because insulin production and insulin response are not enough | A1C, fasting blood glucose, oral glucose tolerance test, or random glucose with symptoms | Needs ongoing diabetes care to reduce complications |
| Type 1 diabetes | Autoimmune loss of insulin-making beta cells | Glucose testing plus clinical evaluation, often autoantibodies and C-peptide | Requires insulin treatment |
How does insulin normally control blood sugar?
Insulin works like a signal that helps glucose leave the bloodstream after meals. In a healthy response, blood glucose rises after eating, the pancreas releases insulin, cells take in glucose, and blood sugar moves back toward a normal range 1.
Insulin also tells the liver what to do with energy. After a meal, the liver stores extra glucose. Between meals, the liver releases stored glucose so the brain and body have a steady fuel supply 1.
This system changes hour by hour. Sleep, exercise, stress hormones, illness, medicines, meal size, and body weight can all change how much insulin the body needs at a given time 1, 2.
What happens during insulin resistance?
Insulin resistance means muscle, fat, and liver cells need a stronger insulin signal to handle the same amount of glucose. The pancreas may compensate by making higher insulin levels, which can keep glucose normal for months or years 1.
When the pancreas can no longer keep up, blood glucose may rise. This is why insulin resistance often sits upstream of prediabetes and type 2 diabetes, but it is not the same diagnosis 1, 2.
Insulin resistance is also linked with metabolic syndrome, which often includes higher waist size, high triglycerides, low HDL cholesterol, elevated blood pressure, and elevated fasting glucose. These patterns matter because they raise long-term cardiometabolic risk 2.
Can you be insulin resistant and not have diabetes?
Yes. Insulin resistance can be present while A1C and fasting blood glucose are still normal, especially if the pancreas is still making enough insulin to compensate 1.
That is one reason symptoms are not enough. A person can feel well and still have insulin resistance, prediabetes, or early type 2 diabetes. The CDC notes that insulin resistance and prediabetes often have no clear symptoms early on 1.
If you are trying to understand your own numbers, our guide to normal blood sugar levels explains fasting glucose, after-meal glucose, and A1C ranges in plain language.
How do prediabetes and type 2 diabetes fit into the timeline?
Prediabetes and type 2 diabetes often develop along a timeline, but the timeline is not automatic. Many people can improve insulin sensitivity and reduce diabetes risk with lifestyle changes, weight loss when appropriate, and clinician-guided care 1, 3.
Insulin resistance
This can be the earliest stage. Cells are less responsive to insulin, and the pancreas may make more insulin to keep blood sugar in range 1.
Prediabetes
Prediabetes means blood glucose is higher than normal but not high enough for diabetes. The American Diabetes Association lists common diagnostic ranges as A1C 5.7% to 6.4%, fasting plasma glucose 100 to 125 mg/dL, or 2-hour oral glucose tolerance test 140 to 199 mg/dL 2.
Type 2 diabetes
Type 2 diabetes is usually diagnosed when A1C is 6.5% or higher, fasting plasma glucose is 126 mg/dL or higher, a 2-hour oral glucose tolerance test is 200 mg/dL or higher, or a random plasma glucose is 200 mg/dL or higher with classic symptoms 2.
How this differs from type 1 diabetes
Type 1 diabetes is different. It is commonly caused by autoimmune destruction of insulin-producing beta cells, so the body cannot make enough insulin. It requires insulin therapy and should not be managed as simple insulin resistance 2.
How can you tell if it is insulin resistance or diabetes?
Blood testing is the main way to tell. Symptoms, body size, cravings, fatigue, or wearable glucose data can raise useful questions, but they do not diagnose insulin resistance, prediabetes, or diabetes by themselves 2.
Why symptoms are not enough
Early insulin resistance and prediabetes often have no symptoms. Some people with type 2 diabetes also feel normal at diagnosis, which is why screening is recommended for many adults based on age, weight, pregnancy history, and other risk factors 2.
Common blood tests clinicians use
- A1C: estimates average blood glucose over about 2 to 3 months and does not require fasting 2.
- Fasting blood glucose: checks glucose after no calories for at least 8 hours 2.
- Oral glucose tolerance test: measures fasting glucose and glucose after a glucose drink, often 2 hours later 2.
- Lipids: triglycerides, LDL cholesterol, and HDL cholesterol help clinicians assess metabolic syndrome and cardiovascular risk 2.
What to ask your clinician about A1C, fasting glucose, and oral glucose tolerance testing
Ask which test fits your situation and whether results should be repeated. A1C can be less reliable in some blood disorders, pregnancy, kidney disease, or situations that affect red blood cells, so clinicians may choose fasting glucose or an oral glucose tolerance test instead 2.
When high blood sugar symptoms need prompt care
Get prompt medical care for severe thirst, frequent urination, dehydration, vomiting, confusion, rapid breathing, chest pain, shortness of breath, or fruity-smelling breath. These can be signs of dangerous high blood sugar or diabetic ketoacidosis, especially in people with type 1 diabetes or insulin deficiency 2.
What signs can point to insulin resistance or high blood sugar?
Signs can offer clues, but they are not proof. The same symptom can have many causes, so the safest next step is lab testing and a clinician review 1, 2.
Possible signs of insulin resistance
- Acanthosis nigricans, which means darker, velvety skin patches often seen on the neck or underarms 1.
- Higher waist size or visceral fat, especially with high triglycerides or low HDL cholesterol 2.
- PCOS, or polycystic ovary syndrome, which is often linked with insulin resistance 2.
- High triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood pressure, or fatty liver risk patterns 2.
Possible signs of diabetes
- More thirst or urination than usual 2.
- Unexplained weight loss, especially if rapid or paired with fatigue 2.
- Blurry vision, slow-healing wounds, or frequent infections 2.
- Nausea, vomiting, confusion, or dehydration, which should be treated as urgent if severe 2.
Why many people have no clear symptoms
Blood sugar can rise slowly. The body may adapt at first, so symptoms may appear late. This is why risk-based screening is often more useful than waiting for a clear warning sign 2.
What raises the risk of insulin resistance and type 2 diabetes?
Risk usually comes from several factors together, not one single cause. Body weight, waist fat, family history, movement, sleep, medications, pregnancy history, and lipid patterns can all matter 1, 2.
Body weight and waist fat
Higher body weight and visceral fat are strongly linked with insulin resistance and type 2 diabetes risk. Weight loss can improve insulin sensitivity for many people when excess weight is part of the picture 1, 3.
Physical inactivity
Muscle is a major glucose user. Regular activity helps muscle take up glucose and can improve insulin sensitivity, even before major weight loss occurs 1, 4.
Family history
A family history of type 2 diabetes raises risk, but it does not make diabetes certain. It does mean screening and prevention steps may deserve more attention 2.
Triglycerides and cholesterol patterns
High triglycerides, low HDL cholesterol, and elevated blood pressure often travel with insulin resistance. Clinicians often review these together because metabolic syndrome raises cardiovascular risk 2.
PCOS, gestational diabetes history, sleep, stress, and medications
PCOS, prior gestational diabetes, poor sleep, chronic stress, smoking, glucocorticoids, and some antipsychotic medications can raise metabolic risk. If one applies to you, it is worth asking a clinician whether and when to screen 2.
What helps improve insulin resistance first?
Insulin sensitivity often improves with a set of basics: movement, resistance training, weight loss when clinically appropriate, balanced eating, better sleep, stress care, and not smoking. There is no single fastest fix that works for everyone 1, 3.
Physical activity and resistance training
Aerobic exercise and resistance training both help glucose metabolism. In a randomized trial of people with overweight or obesity after breast cancer treatment, combined aerobic and resistance exercise improved features of metabolic syndrome and related biomarkers in the studied group 4.
Resistance exercise has also been studied in gestational diabetes. In a randomized trial, resistance exercise improved blood glucose outcomes in that pregnancy-specific population, but those results should not be treated as a stand-alone plan for all diabetes 5.
Weight loss when clinically appropriate
The Diabetes Prevention Program found that an intensive lifestyle program lowered diabetes incidence in high-risk adults compared with placebo, with metformin also lowering risk but by a smaller amount in the overall study population 3. Individual results vary.
If excess weight and blood sugar risk overlap for you, our article on weight loss for prediabetes walks through realistic goals and testing follow-up.
Balanced eating patterns
Balanced eating for insulin resistance usually means enough protein and fiber, fewer sugar-sweetened drinks, more minimally processed foods, and a pattern you can maintain. Eating timing can affect metabolism in humans; one controlled feeding trial found that delayed eating affected weight and metabolic measures compared with daytime eating 6.
Sleep, stress, and smoking
Sleep loss, chronic stress, and smoking can worsen metabolic risk. Improving these does not replace diabetes care, but it can support the same insulin-sensitivity goals as nutrition and exercise 1, 2.
Why there is no single fastest fix
Insulin resistance has many inputs. A plan that is too strict may work for a week and fail by the next month. The better target is a plan your clinician agrees is safe and that you can repeat.
Where do medications fit for insulin resistance, prediabetes, or diabetes?
Medication decisions depend on the diagnosis, goals, risk level, and safety profile. Insulin resistance by itself is not usually treated the same way as diagnosed type 2 diabetes 2.
Why insulin resistance itself is not diagnosed or treated the same way as diabetes
There is no single home test that diagnoses insulin resistance for everyone. Clinicians often focus on A1C, fasting glucose, oral glucose tolerance testing, lipids, blood pressure, waist size, pregnancy history, and medication history 2.
Metformin and diabetes-risk discussions
Metformin is a common type 2 diabetes medication and is sometimes discussed for diabetes prevention in higher-risk prediabetes, which is not an FDA-approved indication for metformin. In the Diabetes Prevention Program, metformin reduced diabetes incidence compared with placebo, while intensive lifestyle intervention had the larger effect in the overall trial 3.
For a deeper look, see our guide to metformin and weight loss. Do not start, stop, or change metformin or any diabetes medication without your prescribing clinician.
GLP-1 and GIP/GLP-1 medications for weight and type 2 diabetes contexts
Ozempic (semaglutide, a GLP-1 receptor agonist), Wegovy (semaglutide, a GLP-1 receptor agonist), and Rybelsus (oral semaglutide, a GLP-1 receptor agonist) are FDA-approved brand medications for specific diabetes or weight-management indications depending on the product label 7, 8, 12. Compounded semaglutide via a 503A pharmacy is a separate compounded prescription path and is not FDA-approved.
Mounjaro (tirzepatide, a dual GIP/GLP-1 receptor agonist) and Zepbound (tirzepatide, a dual GIP/GLP-1 receptor agonist) are FDA-approved brand medications for specific diabetes or weight-management indications depending on the product label 9, 10. In a phase 1 randomized trial in adults with type 2 diabetes, subcutaneous tirzepatide improved measures of pancreatic islet function and insulin sensitivity versus placebo or semaglutide; this was a study of the active ingredient in a specific trial setting, not proof of outcomes for compounded formulations 11.
Other incretin medicines include dulaglutide, a GLP-1 receptor agonist, and liraglutide, a GLP-1 receptor agonist. Which medication, if any, fits depends on diagnosis, contraindications, other medicines, pregnancy plans, side effects, cost, and follow-up needs 2.
Why medication choice depends on diagnosis, goals, risks, and eligibility
GLP-1 and GIP/GLP-1 medications can cause side effects such as nausea, vomiting, diarrhea, constipation, and abdominal pain, and labels include warnings and contraindications that clinicians must review before prescribing 7, 8, 9, 10. A weight-loss plan is not a substitute for diabetes diagnosis or diabetes management.
3-min quiz
Considering weight-loss treatment with metabolic risk in mind?
Chia offers clinician-reviewed compounded semaglutide injection and compounded tirzepatide tablets or injections for eligible patients. A licensed US provider reviews your intake and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded medications are made by state-licensed 503A pharmacies, but compounded drugs are not FDA-approved.
Weight-loss treatment at Chia when insulin resistance is part of the picture
Chia may be relevant when excess weight is part of the metabolic picture and you want a licensed-provider review for prescription weight-loss treatment. We do not replace diabetes diagnosis, urgent care, or ongoing diabetes management with your primary care clinician or endocrinologist.
Who Chia may be relevant for
At Chia, care starts online with a health questionnaire. A licensed US provider reviews your history, goals, medications, and safety factors, then prescribes only if treatment is clinically appropriate. Patients can message the care team through the portal between visits.
Compounded semaglutide injection at Chia
Chia offers compounded semaglutide as an injection, with plans currently starting at $249/month. Semaglutide is the active ingredient studied in FDA-approved GLP-1 medications, but compounded semaglutide is not FDA-approved and does not have FDA-evaluated outcomes data.
Compounded tirzepatide tablets or injections at Chia
Chia offers compounded tirzepatide as tablets or injections. Plans currently start at $249/month for tablets and $299/month for injections. Tirzepatide is a dual GIP/GLP-1 receptor agonist; compounded tirzepatide is not the same as, generic of, or equivalent to any brand-name drug.
Microdosing plans when clinically appropriate
Microdosing plans are available for compounded semaglutide and compounded tirzepatide when clinically appropriate. These compounded and nonstandard microdosing approaches are not FDA-approved or FDA-evaluated. Dosing is provider-guided and adjusted over time; we do not recommend changing diabetes or weight-loss medication doses without the prescribing clinician.
| Chia option | Forms Chia offers | Current starting price | May fit someone who prefers |
|---|---|---|---|
| Compounded semaglutide | Injection | From $249/month | A once-weekly injectable GLP-1 path reviewed by a licensed provider |
| Compounded tirzepatide | Tablets or injection | Tablets from $249/month; injection from $299/month | A dual GIP/GLP-1 path with a choice of tablet or injection when eligible |
| Weight + Energy protocol | NAD+ injection, which is not FDA-approved for weight loss, plus choice of GLP-1 | From $309/month | A provider-reviewed weight-loss plan that also includes NAD+ injection |
| Weight + Muscle protocol | Sermorelin injection, which is not FDA-approved for weight loss, plus choice of GLP-1 | From $329/month | A provider-reviewed weight-loss plan that also includes sermorelin injection |
What Chia does not replace: diabetes diagnosis, urgent care, or ongoing diabetes management
If you have known diabetes, possible type 1 diabetes, pregnancy-related glucose issues, very high blood sugar, or symptoms of dehydration or ketoacidosis, you need appropriate medical care. Chia’s weight-loss treatment can be one part of a broader plan only when a licensed provider determines it is safe and appropriate.
What should you do next if you are worried about insulin resistance or diabetes?
Next steps should start with testing and a clinician review, not guesswork. If your concern is mainly weight and metabolic risk, a clinician-reviewed weight-loss option may also be worth discussing.
Ask for appropriate lab testing
Ask a clinician whether A1C, fasting blood glucose, an oral glucose tolerance test, lipids, liver enzymes, kidney function, or urine albumin testing makes sense for you. The right set depends on your history and risk factors 2.
Review weight, blood pressure, lipids, and family history
Blood sugar is only one part of cardiometabolic health. Weight pattern, blood pressure, triglycerides, LDL cholesterol, HDL cholesterol, smoking, sleep, family history, and pregnancy history can all change your risk profile 2. Our guide to weight loss and diabetes explains how these pieces connect.
Seek urgent care for severe symptoms
Do not wait for an online weight-loss visit if you have severe thirst, confusion, vomiting, dehydration, chest pain, shortness of breath, or signs of diabetic ketoacidosis. Those symptoms need urgent medical care 2.
Consider a clinician-reviewed weight-loss option if eligible
If excess weight is part of your insulin-resistance risk, weight-loss treatment may be one tool. You can also read more about type 2 diabetes and weight loss or metabolic syndrome and weight loss before deciding what to ask your clinician.
3-min quiz
Start with a licensed-provider review
If weight-loss treatment feels relevant to your metabolic health goals, Chia’s online visit lets a licensed US provider review your health history and eligibility. Prescriptions are never guaranteed. Chia’s compounded medications are dispensed by state-licensed 503A pharmacies and shipped to your door, but compounded drugs are not FDA-approved.
FAQ
You cannot know for sure from symptoms alone. A clinician usually checks A1C, fasting blood glucose, and sometimes an oral glucose tolerance test, along with your history and risk factors 2.
Yes. Early on, the pancreas may make extra insulin to keep blood sugar normal. That is why someone can have insulin resistance before prediabetes or type 2 diabetes appears on standard glucose tests 1.
GLP-1 and GIP/GLP-1 medications are used in specific diabetes and weight-management contexts depending on the product and patient 7, 8, 9, 10. They are not a stand-alone diagnosis or treatment for insulin resistance itself. Compounded versions are not FDA-approved and do not have FDA-evaluated outcomes data.
Home insulin testing is not a standard way to diagnose insulin resistance or diabetes. If you are worried, ask a clinician about A1C, fasting glucose, oral glucose tolerance testing, lipids, and other labs that fit your situation 2.
References
- 1.Centers for Disease Control and Prevention. About Insulin Resistance and Type 2 Diabetes. CDC. 2024.
- 2.American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- 3.Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002.
- 4.Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, et al. Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology. 2018.
- 5.Xie Y, Zhao H, Zhao M, et al. Effects of Resistance Exercise on Blood Glucose Level and Pregnancy Outcome in Patients with Gestational Diabetes Mellitus: A Randomized Controlled Trial. BMJ Open Diabetes Research & Care. 2022.
- 6.Allison KC, Hopkins CM, Ruggieri M, et al. Prolonged, Controlled Daytime versus Delayed Eating Impacts Weight and Metabolism. Current Biology. 2021.
- 7.U.S. Food and Drug Administration. Ozempic (semaglutide) Injection Prescribing Information. 2025.
- 8.U.S. Food and Drug Administration. Wegovy (semaglutide) Injection Prescribing Information. 2025.
- 9.U.S. Food and Drug Administration. Mounjaro (tirzepatide) Injection Prescribing Information. 2025.
- 10.U.S. Food and Drug Administration. Zepbound (tirzepatide) Injection Prescribing Information. 2025.
- 11.Heise T, Mari A, DeVries JH, et al. Effects of Subcutaneous Tirzepatide versus Placebo or Semaglutide on Pancreatic Islet Function and Insulin Sensitivity in Adults with Type 2 Diabetes: A Multicentre, Randomised, Double-Blind, Parallel-Arm, Phase 1 Clinical Trial. The Lancet Diabetes & Endocrinology. 2022.
- 12.U.S. Food and Drug Administration. Rybelsus (semaglutide) Tablets Prescribing Information. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
